Physician profile
Paschal Wilson
NPI 1619975521
$7,394.57
in general payments reported to CMS, 2019-2025
59 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $723 · 2021: $460 · 2022: $1,304 · 2023: $1,412 · 2024: $1,078 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.95 |
| Education | $148.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $740.15 | 2022-2025 | Trodelvy |
| Celgene Corporation | $638.92 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $602.51 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $508.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $437.24 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $423.46 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $398.97 | 2019-2023 | Imbruvica |
| Janssen Biotech, INC. | $367.95 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Glaxosmithkline, LLC. | $359.89 | 2019-2025 | Zejula, Jemperli, Ojjaara |
| Astrazeneca Pharmaceuticals Lp | $336.82 | 2019-2025 | Enhertu, Imfinzi |
| Abbvie INC. | $216.78 | 2019-2025 | Venclexta |
| Genzyme Corporation | $169.32 | 2019-2025 | |
| Amgen INC. | $154.06 | 2019-2023 | Lumakras |
| Daiichi Sankyo INC. | $152.43 | 2020-2022 | |
| Eisai INC. | $129.97 | 2019-2023 |
Show all 58 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paschal Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.